Development asset linked to DBV Technologies in public FDA and regional records.
pharma · Peanut allergy · Allergy, Peanut
DBV Technologies
DBV Technologies drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Chatillon, FR HQ
220 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Chatillon, FR
- Employees
- 220
- Programs
- 3
- Drugs
- 7
- Patents
- 0
DBV Technologies pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
DBV Technologies drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
defatted powder of arachis hypogaea l., semen (peanuts)
Various (V01)Various (V01) compound in DBV Technologies's portfolio. Mechanism: Food allergy desensitisation.
- Mechanism
- Food allergy desensitisation
-
Development asset linked to DBV Technologies in public FDA and regional records.
-
Development asset linked to DBV Technologies in public FDA and regional records.
-
Development asset linked to DBV Technologies in public FDA and regional records.
-
Development asset linked to DBV Technologies in public FDA and regional records.
-
Development asset linked to DBV Technologies in public FDA and regional records.